down arrow

SUSMED, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3319150003
JPY
558.00
-150 (-21.19%)

Aug 10

TKS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Peptidream, Inc.
Cyfuse Biomedical KK
MEDINET Co., Ltd.
OncoTherapy Science, Inc.
Oncolys BioPharma, Inc.
Carna Biosciences, Inc.
Chiome Bioscience, Inc.
StemCell Institute
SUSMED, Inc.
GNI Group Ltd.
Stella Pharma Corp.

Why is SUSMED, Inc. ?

1
Poor Management Efficiency with a low ROE of 0.04%
  • The company has been able to generate a Return on Equity (avg) of 0.04% signifying low profitability per unit of shareholders funds
2
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -215.97
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -215.97
  • The company has been able to generate a Return on Equity (avg) of 0.04% signifying low profitability per unit of shareholders funds
3
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0.04%
4
Negative results in Mar 26
  • NET SALES(HY) At JPY 184.87 MM has Grown at -52.13%
  • NET PROFIT(HY) At JPY -210.77 MM has Grown at -1,149.8%
  • ROCE(HY) Lowest at -11.25%
5
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -16.21%, its profits have fallen by -76.2%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is SUSMED, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
SUSMED, Inc.
-33.73%
0.38
63.25%
Japan Nikkei 225
60.14%
2.04
29.37%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-19.40%
EBIT Growth (5y)
-719.62%
EBIT to Interest (avg)
-286.28
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.01
Sales to Capital Employed (avg)
0.09
Tax Ratio
0.65%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0.04%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.05
EV to EBIT
-17.25
EV to EBITDA
-17.53
EV to Capital Employed
56.86
EV to Sales
31.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-329.69%
ROE (Latest)
-12.08%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company
NET PROFIT(HY)

Higher at JPY -210.77 MM

RAW MATERIAL COST(Y)

Fallen by 0.95% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 196.08 times

NET SALES(Q)

At JPY 139.43 MM has Grown at 16.05%

-19What is not working for the Company
NET SALES(HY)

At JPY 184.87 MM has Grown at -52.13%

NET PROFIT(HY)

At JPY -210.77 MM has Grown at -1,149.8%

ROCE(HY)

Lowest at -11.25%

DEBT-EQUITY RATIO (HY)

Highest at -96.33 %

Here's what is working for SUSMED, Inc.

Net Profit
Higher at JPY -210.77 MM
than preceding 12 month period ended Mar 2026
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (JPY MM)

Net Sales
At JPY 139.43 MM has Grown at 16.05%
over average net sales of the previous four periods of JPY 120.15 MM
MOJO Watch
Near term sales trend is positive

Net Sales (JPY MM)

Inventory Turnover Ratio
Highest at 196.08 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost
Fallen by 0.95% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for SUSMED, Inc.

Net Profit
At JPY -210.77 MM has Grown at -1,149.8%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (JPY MM)

Debt-Equity Ratio
Highest at -96.33 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."